CDK4/6 inhibitors combined with aromatase inhibitors (CDK4/6 inhibitor + AI) demonstrate efficacy in metastatic HR+ breast cancer, with real-world evidence showing improved overall and progression-free survival compared to AI alone [157,158]. Here, CDK4 is linked to breast cancer.